Thromb Haemost 2011; 106(03): 389-390
DOI: 10.1160/TH11-08-0521
Invited Editorial Focus
Schattauer GmbH

Prothrombin complex concentrates for reversal of vitamin K antagonists: Assessing the risks

Michael B. Streiff
1   Johns Hopkins Anticoagulation Management Service and Outpatient Clinics and Johns Hopkins Special Coagulation Laboratory, Baltimore, Maryland, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 22. Juli 2011

Accepted after major revision: 01. August 2011

Publikationsdatum:
24. November 2017 (online)

 

 
  • References

  • 1 Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-1419.
  • 2 Budnitz DS, Shehab N, Kegler SR. et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147: 755-765.
  • 3 Fang MC, Go AS, Chang Y. et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700-705.
  • 4 Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood 2011; 117: 6091-6099.
  • 5 Watson HG, Baglin T, Laidlaw SL. et al. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anti-coagulation with warfarin. Br J Haematol 2001; 115: 145-149.
  • 6 Lee SB, Manno EM, Layton KF. et al. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67: 1272-1274.
  • 7 Goldstein JN, Thomas SH, Frontiero V. et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-155.
  • 8 Makris M, Greaves M, Phillips WS. et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
  • 9 Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
  • 10 Boulis NM, Bobek MP, Schmaier A. et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1119.
  • 11 Cartmill M, Dolan G, Byrne JL. et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 458-461.
  • 12 Leissinger CA, Blatt PM, Hoots WK. et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83: 137-143.
  • 13 Pabinger I, Brenner B, Kalina U. et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
  • 14 Holland L, Warkentin TE, Refaai M. et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supra-therapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49: 1171-1177.
  • 15 Lankiewicz MW, Hays J, Friedman KD. et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-970.
  • 16 Warren O, Simon B. Massive, fatal, intracardiac thrombosis associated with prothrombin complex concentrate. Ann Emerg Med 2009; 53: 758-761.
  • 17 Dentali F, Marchesi C, Pierfranceschi MG. et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin k antagonists. A meta-analysis Thromb Haemost 2011; 106: 429-438.
  • 18 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
  • 19 Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost 2010; 104: 1099-1105.
  • 20 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.